Craft

Boehringer Ingelheim

Revenue

€20.6 B

FY, 2021

Boehringer Ingelheim Summary

Company Summary

Overview
Boehringer Ingelheim International is a pharmaceutical company engaged in human and animal health, and biopharmaceutical contract manufacturing. It focuses on drug discovery and development and offering treatment of heart, metabolic, lung, skin, and retinal diseases, as well as cancer, and mental disorders. The company also develops solutions and provide services to protect animals from disease and pain by providing vaccines, parasiticides, and therapeutics, complemented by diagnostics and monitoring platforms.
Type
Subsidiary
Status
Active
Founded
1885
HQ
Ingelheim am Rhein, DE | view all locations
Website
https://www.boehringer-ingelheim.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Hubertus von Baumbach

    Hubertus von Baumbach, Chairman of the Board of Managing Directors

    • Carinne Brouillon

      Carinne Brouillon, Member of the Board of Managing Directors, Human Pharma Business Unit

    • Michel Pairet

      Michel Pairet, Member of the Board of Managing Directors, Innovation Unit

    • Jean Scheftsik de Szolnok

      Jean Scheftsik de Szolnok, Member of the Board of Managing Directors, Animal Health Business Unit

    Operating MetricsView all

    Manufacturing Facilities (Human Pharmaceuticals)

    20
    25.0%

    FY, 2018

    Active Clinical Studies

    500
    11.1%

    FY, 2021

    New Products

    126
    47.5%

    FY, 2021

    LocationsView all

    70 locations detected

    • Ingelheim am Rhein, RP HQ

      Germany

      Binger Str. 173

    • Duluth, GA

      United States

      3239 Satellite Blvd NW

    • Ridgefield, CT

      United States

      900 Ridgebury Rd

    • Algiers, Wilaya d'Alger

      Algeria

      Coopérative El Yasmine, 29 route du stade, Ouled Fayet

    • Munro, Provincia de Buenos Aires

      Argentina

      piso 2, EAA, Cazadores de Coquimbo 2841

    • Macquarie Park, NSW

      Australia

      Level 1/78 Waterloo Rd

    and 64 others

    Boehringer Ingelheim Financials

    Summary Financials

    Revenue (FY, 2021)
    €20.6B
    Gross profit (FY, 2021)
    €17.8B
    Net income (FY, 2021)
    €3.4B
    Cash (FY, 2021)
    €2.3B
    EBIT (FY, 2021)
    €4.7B

    Footer menu